David A. Arkowitz's Insider Trades & SAST Disclosures
David A. Arkowitz's most recent trade in Kineta Inc was a trade of 12,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Sept. 4, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David A. Arkowitz.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kineta Inc | David A. Arkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | A. Arkowitz David | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 287,905 | 287,905 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Arkowitz David A. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 213,750 | 213,750 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 35,625 | 35,625 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | David Arkowitz A. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 10,625 | 31,875 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | David Arkowitz A. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 10,625 | 186,381 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Arkowitz A. David | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.08 per share. | 14 Feb 2024 | 3,939 | 182,442 (0%) | 0% | 1.1 | 4,254 | Common Stock |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 42,500 | 166,613 (0%) | 0% | 0 | Common stock | |
| Kineta Inc | David A. Arkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Kineta Inc | David A. Arkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 42,500 | 42,500 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 3.15 per share. | 05 Jul 2022 | 63,492 | 65,492 (0%) | 0% | 3.2 | 200,000 | COMMON STOCK |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 42,500 | 112,992 (0%) | 0% | 0 | Common stock | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 5,000 | 0 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 5,000 | 70,492 (0%) | 0% | 0 | Common stock | |
| Seres Therapeutics Inc | David A. Arkowitz | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 190,000 | 190,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges